Shouyao Holdings Beijing Co. Ltd. Class ASSE: 688197

Announcement on Voluntary Disclosure of the Acceptance of New Drug Application for the ALK inhibitor Conteltinib (CT-707)

· Issued by Shouyao Holdings Beijing Co. Ltd. Class A via Shanghai Stock Exchange
Announcement on Voluntary Disclosure of the Acceptance of New Drug Application for the ALK inhibitor Conteltinib (CT-707)

The abstract is for reference only. Please refer to the full text of the announcement on the very day.

Link of Full Text for Reference:
View Attachment

Company analysis